资源描述：
《低分子肝素在慢性阻塞性肺病急性加重期患者中的应用》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。
1、低分子肝素在慢性阻塞性肺病急性加重期患者中的应用尹华张承双流县第一人民医院呼吸科四川成都610200【摘要】目的：探讨低分子肝素钙在治疗慢性阻塞性肺病急性加重期患者中的临床应用。方法：选取2013年9月至2014年8月收治的98例慢性阻塞性肺病急性加重期患者，将其随机分为治疗组和对照组各49例。对照组患者给予抗感染、低流量吸氧、强心、利尿、扩血管、化痰止咳平喘等常规治疗，治疗组患者在此基础上给予低分子肝素治疗，比较两组患者临床治疗效果、血气分析结果、凝血功能、D二聚体及不良反应情况。结果：治疗组患者治
2、疗总有效率为89.80%,对照组患者治疗总有效率为73.47%,两组比较差异有统计学意义(P<0.05)；两组患者动脉血氧分压、动脉血二氧化碳分压、凝血功能、D二聚体均有明显改善，且治疗组改善情况明显优于对照组(P<0.05);两组患者均未出现严重不良反应。结论：在常规治疗的基础上联合低分子肝素治疗慢性阻塞性肺病，有助于改善患者病情，安全有效，值得推广。【关键词】低分子肝素；抗凝治疗；慢性阻塞性肺病；D二聚体【中图分类号1R563.9【文献标识码】B【文章编号】1674-8999(2015
3、)8-0214-02Lowmolecularweightheparinintheapplicationofchronicobstructivepulmonarydisease(copd)withacuteexacerbationstageYINHua,ZHANGChengTheFirstPeople’sHospitalofShuangliuCounty,chengdu610200【Abstract】Objective:toinvestigatetheapplicationofthelowmolecul
4、arweightheparininthetreatmentofchronicobstructivepulmonarydisease(copd)withacuteacutestage.Methods：FromSeptember2013toAugust2014atotalof98patientswithchronicobstructivepulmonarydisease(copd)inacuteexacerbationstagewereselectedandrandomlydividedintotreat
5、mentgroupandcontrolgroup49cases.Thepatientsofthecontrolgroupweretreatedwithantibiotics,lowflowoxygen,cardiac,diuretic,vasodilator,spasmolysis,asthmarelief,coughreliefandsputumreduction.Thepatientsintreatmentgroup,inadditiontotheconventionaltherapyusedin
6、thecontrolgroup,werealsotreatedwithlowmolecularweightheparin.Arterialbloodgasindicators,bloodcoagulationindicatorsandD-dimmerofthetwogroupsbeforeandaftertreatmentweredetermined.Twogroupswerecomparedclinicaloutcomes,bloodgasanalysis,coagulation,D-dimerle
7、velandadversereactions.ResultsThetotaleffectiverateinthetreatmentgroupwas89.80%,thetotaleffectiverateinthecontrolgroupwas73.47%,thedifferencewasstatisticallysignificant(P<0.05).Arterialbloodgasindicators,bloodcoagulationindicatorsandD-dimmerofthetwog
8、roupsweresifnificantlybetterthanthoseinthecontrolgroup(P<0.05).Andtheextentsoftheimprovementsinthetreatmentgroupweresignificantlygreaterthanthoseinthecontrolgroup(P<0.05).Noseriousadversereactionsoccurredinthetreatmentgroup
